A novel antagonist of the prostaglandin E 2 EP 4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models

British Journal of Pharmacology

Volumn 160, Issue 2, 2010, Pages 292-310

  Chen, Q ^a   Muramoto, K ^b   Masaaki, N ^b   Ding, Y ^a   Yang, H ^a   MacKey, M ^a   Li, W ^a   Inoue, Y ^b   Ackermann, K ^a   Shirota, H ^a   Matsumoto, I ^c   Spyvee, M ^a   Schiller, S ^a   Sumida, T ^c   Gusovsky, F ^a   Lamphier, M ^a  

^a EISAI RESEARCH INSTITUTE   (United States)

^b Tsukuba Research Laboratories   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

CIA; EP 4 antagonist; EP 4 receptor; GPI induced arthritis model; IFN ; IL 17; IL 23; PGE 2; Th1; Th17

Indexed keywords

1 (3,5 DIMETHYLBENZYL) 2 ETHYL 7,9 DIMETHOXY 10 METHYL 5,10 DIHYDROSPIRO[BENZO[E]IMIDAZO[1,5 A]AZEPINE 1,4' PIPERIDIN] 3(2H) ONE; ER 819762; FREUND ADJUVANT; GLUCOSE 6 PHOSPHATE ISOMERASE; INDOMETACIN; INTERLEUKIN 23; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPERALGESIA; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BENZAZEPINES; CELL DIFFERENTIATION; CELL LINE; COLLAGEN; DISEASE MODELS, ANIMAL; HUMANS; IMIDAZOLES; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; PAIN; RATS; RATS, INBRED F344; RECEPTORS, PROSTAGLANDIN E; SIGNAL TRANSDUCTION; TH1 CELLS;

EID: 77951692935     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00647.x     Document Type: Article

References (43)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S254. (Pubitemid 351415518)
2. Betz M, Fox BS (1991). Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 146 : 108 113.
3. Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McClanahan TK et al. (2009). Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 206 : 533 548.
4. + T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res 66 : 1114 1122. (Pubitemid 43165980)
5. Chizzolini C, Chicheportiche R, Alvarez M, de Rham C, Roux-Lombard P, Ferrari-Lacraz S et al. (2008). Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 112 : 3696 3703.
6. Clark P, Rowland SE, Denis D, Mathieu MC, Stocco R et al. (2008). MF498, a selective E prostaglandin receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther 325 : 425 434.
7. Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M (2008). Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 226 : 87 102.
8. Fujino H, Xu W, Regan JW (2003). Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 278 : 12151 12156. (Pubitemid 36800194)
9. Gold KN, Weyand CM, Goronzy JJ (1994). Modulation of helper T cell function by prostaglandins. Arthritis Rheum 37 : 925 933. (Pubitemid 24184547)
10. Hata AN, Breyer RM (2004). Pharmacology and signalling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103 : 147 166.
11. Higuchi S, Tanaka N, Shioiri Y, Otomo S, Aihara H (1986). Two modes of analgesic action of aspirin, and the site of analgesic action of salicylic acid. Int J Tissue React 8 : 327 331. (Pubitemid 16001081)
12. Hilkens CM, Vermeulen H, Joost van Neerven RJ, Snijdewint FGM, Wierenga EA, Kapsenber ML (1995). Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur J Immunol 25 : 59 63.
13. Honda T, Segi-Nishida E, Miyachi Y, Narumiya S (2006). Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 203 : 325 335. (Pubitemid 43290842)
14. Hunninghake GW, Monick MM, Liu B, Stinski MF (1989). The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. J Virol 63 : 3026 3033. (Pubitemid 19156022)
15. Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Mihira M, Ohsugi Y, Mamura M et al. (2008). Crucial role of IL-6/IL-17 axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 58 : 754 763.
16. Jones RL, Giembycz MA, Woodward DF (2009). Prostanoid receptor antagonists: development strategies and therapeutic applications. Brit J Pharm 158 : 104 145.
17. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB (1996). Anti-cytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF-α, anti-IL-1 α/β, and IL-1Ra. Arthritis Rheum 39 : 797 809. (Pubitemid 26140426)
18. Khayrullina T, Yen JH, Jing H, Ganea D (2008). In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J Immunol 181 : 721 735.
19. Kop EN, Adriaansen J, Smeets TJM, Ver voordeldonk M, Lier RA, Hamann J et al. (2006). CD97 neutralisation increases resistance to collagen-induced arthritis in mice. Arthritis Res Ther 8 : R155.
20. Kuligowska M, Odrowaz-Sypniewska G (2004). Role of interleukin-17 in cartilage and bone destruction in rheumatoid arthritis. Ortop Traumatol Rehabil 6 : 235 241.
21. Kunikata T, Yamane H, Segi E, Matsuoka T, Sugimoto Y et al. (2005). Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nature Immunol 6 : 524 531. (Pubitemid 41716766)
22. Lin CR, Amaya F, Barrett L, Wang H, Takada J, Samad TA et al. (2006). Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319 : 1096 1103.
23. 2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 110 : 651 658. (Pubitemid 34988789)
24. Matsumoto I, Zhang H, Yasukochi T, Iwanami K, Tanaka Y et al. (2008). Therapeutic effects of antibodies to tumor necrosis factor-a, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis. Arthritis Res Ther 10 : R66. (Pubitemid 351895459)
25. 4 antagonist, CJ-042,794, in rat models of pain and inflammation. Eur J Pharm 580 : 116 121.
26. Mustelin M, Tasken K (2003). Positive and negative regulation of T cell activation through kinases and phosphatases. Biochem J 371 : 15 27. (Pubitemid 36458075)
27. Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y et al. (2007). CJ-023,423 a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 322 : 686 694. (Pubitemid 47105812)
28. Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A, Sallusto F (2009). Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells. Eur J Immunol 39 : 1301 1312.
29. Ochi T, Ohkubo O, Mutoh S (2003). Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice. Biochem Pharmacol 66 : 1055 1060. (Pubitemid 37083602)
30. Okano M, Sugata Y, Fujiwara T, Matsumoto R, Nishibori M, Shimizu K et al. (2006). Prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T cell responses by prostaglandin E2. Immunol 118 : 343 352. (Pubitemid 43911647)
31. Regan J (2003). EP2 and EP4 prostanoid receptor signalling. Life Sci 74 : 143 153.
32. Schnurr M, Toy T, Shin A, Wagner M, Cebon J, Maraskovsky E (2005). Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood 105 : 1582 1589. (Pubitemid 40223678)
33. Schulze-Koops H, Kalden JR (2001). The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 15 : 677 691. (Pubitemid 34092508)
34. Sheibanie AF, Tadmori I, Jing H, Vassiliou E, Ganea D (2004). Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J 18 : 1318 1320. (Pubitemid 39561589)
35. Sheibanie AF, Khayrullina T, Safadi FF, Ganea D (2007a). Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum 56 : 2608 2619. (Pubitemid 47237279)
36. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R et al. (2007b). The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23 - >IL-17 axis. J Immunol 178 : 8138 8147. (Pubitemid 46898086)
37. Spyvee M, Shaffer CI, Seletsky BM, Schiller S, Liu J, Li X-YL et al. (2009). WO 2009/064274 A1.
38. Takeuchi K, Tanaka A, Kato S, Aihara, Amagase K 2007). Effect of (S)-4-(1-(5-chloro-2-(4-fluoropheyoxy)benzamido)ethyl) benzoid acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinol mucosa. J Pharmacol Exp Ther 322 : 903 912. (Pubitemid 47295797)
39. Verri WA Jr., Cunha TM, Parada CA, Poole S, Cunha FQ et al. (2006). Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther 112 : 116 138. (Pubitemid 44301486)
40. Williams RO (2004). Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol Med 98 : 207 216.
41. Williams RO (2006). Pathogenesis and therapy of rheumatoid arthritis. Ernst Schering Found Symp Proc 1 : 107 130.
42. Williams RO, Marinova-Mutafchieva L, Feldmann M, Maini RN (2000). Evaluation of TNF-α and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-α/anti-CD4 therapy. J Immunol 165 : 7240 7245. (Pubitemid 32001202)
43. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K et al. (2009). Prostaglandin E(2)-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009 May 24. [Epub ahead of print ].